Education
About Us
Working with TipRanks
Follow Us
I-MAB (IMAB)
NASDAQ:IMAB
IMAB Stock Chart & Stats
$5.79
$0.18(18.08%)
At close: 4:00 PM EST
$5.79
$0.18(18.08%)
Day’s Range― - ―
52-Week Range$0.60 - $6.16
Previous CloseN/A
Volume876.01K
Average Volume (3M)1.69M
Market Cap
$377.75M
Enterprise Value$35.53M
Total Cash (Recent Filing)$165.61M
Total Debt (Recent Filing)$3.48M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Nov 13, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding81,660,350
10 Day Avg. Volume2,288,003
30 Day Avg. Volume1,691,940
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market Cap0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$7.40Price Target Upside27.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentGivastomig’s upcoming Ph 1b dose expansion update is a significant value-inflection point for the stock, and optimism surrounds the expected clinical data.
Financial PositionThe August 2025 financing extends cash runway into the fourth quarter of 2028, allowing I-Mab to carry givastomig through a randomized Phase 2 trial.
Pipeline ExpansionI-Mab announced it will be expanding clinical development of givastomig (giva) to include other CLDN18.2 positive tumors including PDAC and biliary tract cancer (BTC).
Bears Say
Market PerceptionI-Mab shares fell ~20% following a New York Times article, which is seen as an unwarranted mispricing due to the mischaracterization of I-Mab as a Chinese drugmaker.
Regulatory ConcernsThe NY Times article focuses on China drug import restrictions, which does not apply to I-Mab. I-Mab is a U.S.-based biotech company with all clinical operations and personnel based in the U.S.
I-MAB News
IMAB FAQ
What was I-MAB’s price range in the past 12 months?
I-MAB lowest stock price was $0.59 and its highest was $6.16 in the past 12 months.
What is I-MAB’s market cap?
I-MAB’s market cap is $377.75M.
When is I-MAB’s upcoming earnings report date?
I-MAB’s upcoming earnings report date is Nov 13, 2025 which is in 29 days.
How were I-MAB’s earnings last quarter?
I-MAB released its earnings results on Aug 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.024.
Is I-MAB overvalued?
According to Wall Street analysts I-MAB’s price is currently Undervalued.
Does I-MAB pay dividends?
I-MAB does not currently pay dividends.
What is I-MAB’s EPS estimate?
I-MAB’s EPS estimate is -0.04.
How many shares outstanding does I-MAB have?
I-MAB has 81,660,350 shares outstanding.
What happened to I-MAB’s price movement after its last earnings report?
I-MAB reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 7.363%.
Which hedge fund is a major shareholder of I-MAB?
Currently, no hedge funds are holding shares in IMAB
I-MAB Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.40 (27.81% Upside)
$7.40 (27.81% Upside)
Blogger Sentiment
Bullish
IMAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 26.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 41.6%
Last 30 Days ▲ 41.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
355.90%
12-Months-Change
Fundamentals
Return on Equity
-22.44%
Trailing 12-Months
Asset Growth
-42.27%
Trailing 12-Months
Company Description
I-MAB
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
IMAB Stock 12 Month Forecast
Average Price Target
$7.40
▲(27.81% Upside)
Technical Analysis
Lineage Therap
―
Larimar Therapeutics
―
Assembly Biosciences
―
Design Therapeutics
―
Immuneering
―
Ownership Overview
5.60%
Insiders
0.03% Mutual Funds
9.02% Other Institutional Investors
90.94% Public Companies and
Individual Investors